Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DAGLA | Q9Y4D2 | 9/20 | 0.38 |
| ▸ | ABHD6 | Q9BV23 | 5/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.34 |
| ▸ | DAGLB | Q8NCG7 | 1/20 | 0.34 |
| ▸ | DPP4 | P27487 | 1/20 | 0.34 |
| ▸ | PRKAA2 | P54646 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2616568 | 0.80 | HCRTR1 (0.60) | — | |
| SCHEMBL8154618 | 0.80 | DAGLA (0.36) | DAGLAABHD6DAGLB | |
| SCHEMBL4167672 | 0.78 | RHOC (0.38) | DAGLAABHD6ALDH1A1 | |
| SCHEMBL3496295 | 0.74 | TDP1 (0.35) | DAGLAABHD6 | |
| SCHEMBL4167405 | 0.74 | ALDH1A1 (0.38) | DAGLAALDH1A1SMN1; SMN2 | |
| SCHEMBL2120480 | 0.72 | LTA4H (0.41) | — | |
| SCHEMBL4157352 | 0.72 | MEN1 (0.40) | DAGLAABHD6ALDH1A1HSD11B1DPP4 | |
| SCHEMBL4159081 | 0.72 | KDM4E (0.42) | DAGLAABHD6ALDH1A1HSD11B1 | |
| SCHEMBL4170825 | 0.67 | DPP4 (0.39) | DAGLAABHD6HSD11B1DAGLBDPP4 | |
| SCHEMBL4163254 | 0.67 | DPP4 (0.39) | DAGLAABHD6HSD11B1DAGLBDPP4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090022670-A1 | NOVEL COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2009-01-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090022670-A1 | NOVEL COMPOUNDS | UGT1A1, UGT2B7, ABCB1 | DAGLA 4103/4885ABHD6 4455/4885ALDH1A1 125/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.